Edesa Biotech organizacji Current ratio
Jaka jest wartość Current ratio organizacji Edesa Biotech?
Wartość Current ratio organizacji Edesa Biotech, Inc. to 1.29
Jaka jest definicja Current ratio?
Wskaźnik bieżącej płynności to wskaźnik płynności, który określa, czy firma ma wystarczające zasoby, aby wywiązać się z zobowiązań krótkoterminowych.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio firm w Health Care sektor na NASDAQ w porównaniu do Edesa Biotech
Czym się zajmuję organizacja Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Firmy z current ratio podobne do Edesa Biotech
- Wartość Current ratio organizacji Berger Paints India to 1.29
- Wartość Current ratio organizacji A2B Australia to 1.29
- Wartość Current ratio organizacji Realites SCA to 1.29
- Wartość Current ratio organizacji Nomura to 1.29
- Wartość Current ratio organizacji Shriram EPC to 1.29
- Wartość Current ratio organizacji Yunhong CTI Ltd to 1.29
- Wartość Current ratio organizacji Edesa Biotech to 1.29
- Wartość Current ratio organizacji Emcor to 1.29
- Wartość Current ratio organizacji Yip's Chemical to 1.29
- Wartość Current ratio organizacji MSP Steel & Power to 1.29
- Wartość Current ratio organizacji Trip Technologies to 1.29
- Wartość Current ratio organizacji Kajima to 1.29
- Wartość Current ratio organizacji National Fittings to 1.29